The Chinnaiyan Lab
Overview and Background
Dr. Arul Chinnaiyan is a molecular pathologist and physician scientist at the leading edge of translational cancer research and precision oncology. Dr. Chinnaiyan completed his undergraduate, M.D., and Ph.D. degrees, as well as his clinical pathology residency, at the University of Michigan. He is currently the S.P. Hicks Endowed Professor of Pathology, Professor of Urology, and Director of the Michigan Center for Translational Pathology at the University of Michigan. He is also a Howard Hughes Medical Institute Investigator and an American Cancer Society Research Professor. He is a member of the American Society for Clinical Investigation, Association of American Physicians, American Academy of Arts and Sciences, National Academy of Inventors, National Academy of Medicine, and the National Academy of Sciences.
The landmark achievement of his group’s work was the discovery of TMPRSS2-ETS gene fusions in a majority of prostate cancers, the first causative gene fusion in a common solid tumor. In 2011, Dr. Chinnaiyan established MI-Oncoseq, the first integrative, comprehensive clinical sequencing approach for advanced cancer patients, which has served as a paradigm for cancer precision medicine. His research also focuses on understanding the non-coding genome of cancer, particularly in the areas of biomarker and therapeutic development. Research in the Chinnaiyan Lab is supported by several entities, including the Howard Hughes Medical Institute, National Cancer Institute, Prostate Cancer Foundation, and Trailsend Foundation, among others. The Chinnaiyan Lab is also committed to supporting the next generation of cancer researchers and provides a vibrant training environment for postdoctoral fellows, graduate students, and undergraduate students.
For more information on the recent research please visit Research focus page.